Clinical Trial Update: Effect of iNO in Patients With Submassive and Massive PE [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating inhaled nitric oxide for submassive and massive pulmonary embolism has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Massive Pulmonary Embolism
• Pulmonary Embolism
• Submassive Pulmonary Embolism

Drugs mentioned

• Inhaled nitric oxide (nitric oxide)

Snippet

Sponsor: University of California, Los Angeles | Conditions: Pulmonary Embolism, Pulmonary Embolism Subacute Massive | Phase 2 | Status: WITHDRAWN